Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Instagram Outage Disrupts Thousands of U.S. Users 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ft. Lauderdale, FL, Feb. 02, 2018 -- OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of patient-centric, clinical data management technology, has completed the acquisition of certain assets and assumed certain liabilities of Algorics, a provider of clinical analytics solutions and software.
This acquisition significantly enhances OmniComm’s product portfolio with advanced data analytics capabilities, specialized algorithms and artificial intelligence/machine learning, developed by Algorics. Acuity is a system-agnostic platform that provides powerful and flexible data aggregation, and visualization that drive actionable knowledge in real time. Acuity improves productivity and minimizes risk in clinical research by providing a clear vision of clinical and operational data.
Acuity will provide enhanced real-time and cross-study reporting capabilities for OmniComm’s TrialMaster® and TrialOne® electronic data capture (EDC) product lines.
“This is definitely a very good acquisition for both OmniComm and Algorics,” said Nithiya Ananthakrishnan, who was the CEO and founder of Algorics. “By joining with OmniComm, we will accelerate our goal of becoming the best-in-class solution for risk-based monitoring and clinical data analytics. We look forward to bringing additional competitive advantages to OmniComm’s customers by delivering end-to-end RBM solutions and specialized data analytics expertise.”
Mr. Ananthakrishnan will assume the role of senior vice president of Data Sciences at OmniComm, reporting to Stephen Johnson, president and CEO of OmniComm.
“Adding this RBM and analytics platform to our existing product lines fills a strong need for our clients,” Mr. Johnson said. “Due to a common technology stack, the Acuity platform perfectly integrates with our TrialMaster and TrialOne solutions. We are excited to share our newest technology with our clients to help them derive more power from their clinical research data.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations (CROs), diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Please visit www.omnicomm.com for more information.
Investor Relations OmniComm Systems, Inc. +1.954.473.1254 [email protected]
